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mean age 46 years) over the 10 years of follow-up was 57%. 
Compared to patients with a baseline BMI (kg/m 2 ) of 20–25, 
a low BMI <20 was associated with higher long-term mortal-
ity (70 vs. 49%, adjusted hazard ratio 1.97, 95% CI 1.04–3.71, 
p = 0.036). A more pronounced weight loss during HSCT (>7 
vs. <2%) was associated with higher risk for bacterial infec-
tions (52 vs. 28%, OR 2.8, 95% CI 0.96–8.18, p = 0.059) and 
fungal infections (48 vs. 23%, OR 3.37, 95% CI 1.11–10.19, p = 
0.032), and longer hospital stays (64 vs. 38 days, adjusted 
mean difference 25.6 days (15.7–35.5), p < 0.001).  Conclu-
sion: In patients with AML, low initial BMI and more pro-
nounced weight loss during HSCT are strong prognostic in-
dicators associated with lower survival and worse disease 
outcomes. Intervention research is needed to investigate 
whether nutritional therapy can reverse these associations. 
 © 2016 S. Karger AG, Basel 
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 Abstract 
 Introduction: In acute myeloid leukemia (AML) patients un-
dergoing allogeneic haematopoietic stem cell transplanta-
tion (HSCT), there is uncertainty about the extent of influ-
ence nutritional parameters have on clinical outcomes. In 
this study, we investigated the association between initial 
body mass index (BMI) and weight loss during HSCT on clin-
ical outcomes in a well-characterised cohort of AML patients. 
 Methods: We analysed data of the Basel stem-cell transplan-
tation registry (‘KMT Kohorte’) including all patients with 
AML undergoing first allogeneic HSCT from January 2003 to 
January 2014. We used multivariable regression models ad-
justed for prognostic indicators (European Group for Blood 
and Marrow Transplantation risk score and cytogenetics). 
 Results: Mortality in the 156 AML patients (46% female, 
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 Introduction 
 Loss of appetite resulting in involuntary weight loss is 
a key symptom of severe illnesses, particularly in different 
types of malignant diseases  [1] . Weight loss associated 
with malignant diseases may result directly from energy 
deprivation due to poor appetite and gastrointestinal fail-
ure but may also be due to dehydration and sarcopenia  [2, 
3] . Particularly, the inflammatory response observed in 
patients with malignant diseases has multiple effects on 
the brain leading to loss of appetite, as well as on the gas-
trointestinal tract with delays in gastric emptying  [4–6] . 
Also, endocrine imbalances associated with malignant 
disease with increases in catabolic hormones (such as glu-
cocorticoid hormones) and a decrease in anabolic hor-
mones (such as testosterone and other sexual steroids) 
further enhance catabolism and aggravate malnutrition 
 [1] . In addition, anti-cancer therapies may negatively af-
fect nutritional intake due to mucositis and nausea  [7] . 
Importantly, the relationship between malignant disease 
and cachexia may well be bi-directional, with malignancy 
and its treatment affecting nutritional status; also malnu-
trition may have a negative influence on recovery from 
disease and the course of illness  [8, 9] .
 Patients undergoing allogeneic haematopoietic stem 
cell transplantation (HSCT) for acute myeloid leukemia 
(AML) are at eminent high risk for nutritional deteriora-
tion. Although AML patients frequently present with a 
normal nutritional status upon initial diagnosis of dis-
ease, they are at risk to experience significant weight loss 
during HSCT  [7] . For this reason, the guidelines of the 
American and European Societies for Parenteral and En-
teral Nutrition (APSEN, ESPEN) stress the importance of 
using nutrition-screening tools to identify those patients 
who require formal nutrition assessment with develop-
ment of a detailed nutrition care plan  [2, 3, 10–12] . They 
also state that nutritional treatment is appropriate in pa-
tients undergoing HSCT if they are malnourished at 
 baseline or if it can be anticipated that patients are unable 
to ingest and/or absorb adequate nutrients for a pro-
longed period of time. There is, however, uncertainty 
about the influence of nutritional parameters at baseline 
and during HSCT on clinical outcomes in specific cancer 
populations, such as AML patients. Also, it remains un-
clear who among the patients undergoing HSCT do or do 
not ultimately benefit from nutritional treatment  [13] . 
Identification of subgroups of patients at highest risk may 
help to close this gap.
 Our aim was therefore to investigate associations of 
initial body mass index (BMI) and maximal weight loss 
during HSCT on mortality, and infectious complica-
tions in a well-characterised cohort of AML patients in-
cluded in our patient registry over a 10-year time peri-
od. In an exploratory analysis, we also investigated dif-
ferences in patients with or without nutritional therapy 
adjusting the analysis for important prognostic indica-
tors.
 Methods 
 Study Design and Setting 
 This is an observational cohort study including consecutive 
AML patients enrolled in the Basel stem-cell transplantation reg-
istry (KMT Kohorte) for undergoing first allogeneic HSCT from 
January 2003 to January 2014. Due to the observational character 
of this study, the Institutional Review Board of the University Hos-
pital Basel (EKNZ) approved the study and waived the need for 
informed consent.
 Study Aims and Hypothesis 
 The overall study aim was to investigate the interrelatedness of 
(a) BMI (kg/m 2 ) before HSCT, (b) weight loss (%) during HSCT, 
and (c) use of nutritional treatment on different patient-relevant 
outcomes. We hypothesised that low pre-transplantation BMI and 
a more pronounced weight loss during HSCT would be strong pre-
dictors for adverse outcomes, and that these associations may be 
reversed by use of nutritional therapy.
 Patient Population 
 We included consecutive patients with a confirmed diagnosis 
of AML receiving HSCT at the University hospital Basel, 
 Switzerland. This institution has been performing transplanta-
tions on patients right from 1973  [14] with a total of more than 
2,000 transplantations being performed until now. Clinical prac-
tice concerning conditioning regime and supportive therapy has 
been successively implemented based on results of current re-
search. Patients younger than 16 years were treated at the Univer-
sitäts-Kinderspital Beider Basel and were thus not considered for 
this analysis. Also, patients undergoing reduced-intensity condi-
tioning, patients with other final diagnoses than AML and patients 
with autologous transplantation were excluded. In addition, we 
excluded all patients who underwent HSCT before 2003. If patients 
underwent more than one transplantation process during 2003–
2014, only the first transplantation episode was recorded and used 
for the analysis. From a total of 709 transplantations, 156 were pa-
tients with AML fulfilling the study criteria and were thus includ-
ed in the final analysis.
 Definitions and Clinical Variables 
 All clinical data were used from the KMT cohort file with com-
pletion by abstraction from the medical charts. To investigate ini-
tial BMI and outcomes, patients were classified as low BMI (<20 
kg/m 2 ), normal BMI (20–25 kg/m 2 ) and high BMI (>25 kg/m 2 ). 
Weight loss during HSCT was defined as the relative difference 
(%) between initial weight and minimal weight during the hospi-
tal stay. Patients were grouped according to their weight loss into 
little weight loss (<2%), moderate weight loss (2–7%) and high 
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weight loss (>7%). Patients were also classified as receiving nutri-
tional therapy or not with any route of support counting as having 
received nutritional therapy. Yet, based on the routine nutritional 
protocol used in the institution, all patients with nutritional ther-
apy received parenteral nutrition (PE), except for one patient who 
received complementary enteral nutrition.
 For all patients, we calculated the European Group for Blood 
and Marrow Transplantation (EBMT) risk score as recommended. 
Genetic risk was also assessed based on the recommendations by 
the Schweizerische Arbeitsgemeinschaft für klinische Krebsforsc-
hung obtained as a result of cytogenetic analyses and grouped into 
low, moderate or high risk.
 Endpoints 
 The primary endpoint of the study was overall survival until 
follow-up. Patients were censored at the last time of follow-up if 
they did not die. Secondary endpoints included in-hospital mortal-
ity, mortality within the first 100 days after transplantation, time 
to engraftment, time to mucositis, time to development of fever 
(first episode), cumulative number of days with fever, recurrent 
episodes of fever, infections during hospital stay (including bacte-
rial, viral and fungal infections), recurrence of disease, graft versus 
host disease (GvHD) of the intestinal tract and the skin, new diag-
noses of infections 1 and 2 years after transplantation and second-
ary cancers within the follow-up period. Aplasia versus engraft-
ment was defined as neutrophil granulocytes <0.5 × 10 9 per litre or 
>0.5 × 10 9 neutrophil granulocytes per litre, respectively.
 Statistical Analysis 
 This report adheres to the STROBE guidelines for reporting 
observational studies  [15] . Discrete variables are expressed as 
counts (percentage) and continuous variables as medians and in-
terquartile ranges or means and SD as appropriate. Frequency 
comparison was done using the chi-square test. To assess the as-
sociation of our main predictors and outcomes, we used regres-
sion models adjusted for main prognostic parameters including 
the EBMT risk score as well as cytogenetics. Other covariates in-
cluded age, gender and comorbidities (coronary heart disease, val-
vular heart disease, congestive heart disease, diabetes, COPD, 
chronic kidney disease, chronic liver disease). We also adjusted 
the analysis regarding nutritional therapy with initial BMI and 
weight loss.
 We used cox models for time-to-event data with reporting of 
hazard ratios (HRs), logistic regression for binary outcomes with 
reporting of ORs and linear regression for continuous outcomes 
with reporting of coefficients corresponding to mean differences.
 We used STATA 12.1 (Stata Corp 2012, College Station, Tex., 
USA). All testing was 2-tailed, with p  ≤ 0.05 considered to indicate 
statistical significance.
 Results 
 Baseline Characteristics 
 A total of 156 patients (46% women, mean age 46 
years) with a confirmed diagnosis of AML were included. 
The main source of stem cells was peripheral blood (n = 
147), but 8 patients received stem cells from bone marrow 
and one patient received cord blood. The overall mortal-
ity rate was 57.1% (n = 89) with a mean time to death of 
12 months (95% CI 9–16) and a mean observation time 
in survivors of 72 months (95% CI 62–82).  Table 1 shows 
patient characteristics of the overall cohort, stratified by 
overall survival status.
 Association of Initial BMI and Outcomes 
 According to the BMI before HSCT, 71 patients had 
normal BMI (20–25 kg/m 2 ), 20 patients had low BMI 
(<20 kg/m 2 ) and 65 patients had high BMI (>25 kg/m 2 ). 
Overall mortality was significantly increased in patients 
with a low BMI before HSCT compared to normal BMI 
(70 vs. 49%) with a HR of 1.97 (95% CI 1.04–3.71, p = 
0.036). There was no significant difference in mortality 
during the index hospital stay and within 100 days. Also, 
no increase in recurrence risk was found ( table 2 ). When 
looking at infectious complications during the initial 
HSCT, low BMI tended to be associated with an earlier 
development of mucositis (HR 1.72, 95% CI 1.00–3.00, 
p = 0.051), while fever, fever days and infections had sim-
ilar patterns of development. Also, outcomes after 1 and 
2 years were similar in all groups.
 Association of Weight Loss and Outcomes 
 There was a mean weight loss of 4% calculated from 
the initial weight before HSCT to the minimal weight 
during the index hospital stay. A more pronounced 
weight loss compared to little weight loss (reference 
group) during HSCT (>7 vs. <2%) was associated with an 
earlier development of fever (HR 1.92, 95% CI 1.09–3.38, 
p = 0.025) and more fever days (adjusted difference 3.45, 
95% CI 0.59–6.32, p = 0.018), as well as high risk for in-
fectious complications including bacterial infections (52 
vs. 28%, OR 2.8, 95% CI 0.96–8.18, p = 0.059) and fungal 
infections (48 vs. 23%, OR 3.37, 95% CI 1.11–10.19, p = 
0.032). Also, the length of stay was significantly increased 
(64 vs. 38 days, adjusted coefficient 25.6, 95% CI 15.7–
35.5, p < 0.001). A more pronounced weight loss was also 
associated with higher mortality during the index hospi-
tal stay (HR 5.59, 95% CI 1.04–29.93, p = 0.044), but re-
sults were not significant for mortality within 100 days 
and overall survival.
 Outcomes in Patients Receiving and Not Receiving 
Nutritional Therapy 
 In an exploratory analysis, we also investigated out-
comes in patients who did receive nutritional treatment 
with patients who did not receive nutritional therapy. A 
total of 90 patients (57%) received nutritional treatment 
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during HSCT with all of them being treated with paren-
teral nutrition (including one patient also receiving com-
plementary enteral nutrition) and 54 patients (60%) re-
ceiving also glutamine as part of the nutritional interven-
tion. This analysis was again adjusted for prognostic 
indicators as well as initial weight and weight loss during 
the index hospital stay. Compared to not receiving nutri-
tional therapy, receiving parenteral nutrition was associ-
ated in the fully adjusted analysis with earlier time to en-
graftment, but also with worse clinical outcomes includ-
ing higher mortality, higher risk for fever and infectious 
complications and also higher GvHD risk (Appendix 1). 
Also, there was a lower risk for infectious complications 
during the first and second year after HSCT. Glutamine 
use compared to using parenteral nutrition without glu-
tamine had similar outcomes except for lower mucositis 
risk but a fourfold increase in clostridium difficile infec-
tion in the adjusted analysis (Appendix 2).
 Discussion 
 Within this cohort of consecutive patients receiving 
HSCT for AML at a University centre in Switzerland, low 
initial BMI proved to be a strong and independent risk 
factor for overall mortality and development of mucosi-
tis, while a more pronounced weight loss during HSCT 
was associated with fever and infectious complications as 
well as mortality. Importantly, patients with a more pro-
nounced weight loss also showed a marked increase in 
length of hospital stay that ranged from 28 to 64 days. 
These data are in line with previous studies from other 
centres and different patient populations and demon-
strate the importance of an impaired nutritional status at 
the start as well as during HSCT as an unfavourable prog-
nostic factor in this patient population.
 Deterioration of nutritional status is a well-known 
and disease-independent risk factor across medical dis-
Table 1.  Patient characteristics
All patients Overall-survivors Overall-nonsurvivors p value
Number of patients 156 67 89
Socio-demographics and nutritional parameters
Female gender 71 (45.5) 33 (49) 38 (43) 0.42
Age at HSCT, mean (SD) 46.4 (12.0) 45.5 (11.2) 47.1 (12.5) 0.42
Initial BMI, kg/m2, mean (SD) 24.7 (4.5) 25.0 (4.6) 24.6 (4.4) 0.57
<20 20 (12.8) 6 (9) 14 (16) 0.16
20–25 71 (45.5) 36 (54) 35 (39)
>25 65 (41.7) 25 (37) 40 (45)
Lowest BMI, kg/m2, mean (SD) 23.7 (4.2) 24.1 (4.3) 23.5 (4.1) 0.37
<20 32 (20.5) 11 (16) 21 (24) 0.54
20–25 72 (46.2) 33 (49) 39 (44)
>25 52 (33.3) 23 (34) 29 (33)
Weight loss during HSCT, %, mean (SD) –4.0 (3.0) –3.5 (2.5) –4.4 (3.3) 0.077
<2 43 (27.6) 19 (28) 24 (27) 0.42
2–7 90 (57.7) 41 (61) 49 (55)
>7 23 (14.7) 7 (10) 16 (18)
Treatment variables
TBI 42 (26.9) 15 (22) 27 (30) 0.27
One HSCTs 135 (86.5) 61 (91) 74 (83) 0.15
More than one HSCTs 21 (13.5) 6 (9) 15 (17)
Comorbidities
Coronary heart disease 7 (4.5) 2 (3) 5 (6) 0.43
Congestive heart failure 8 (5.1) 1 (1) 7 (8) 0.074
Valvular heart disease 9 (5.8) 3 (4) 6 (7) 0.55
Diabetes mellitus 6 (3.8) 3 (4) 3 (3) 0.72
COPD 3 (1.9) 2 (3) 1 (1) 0.40
Chronic kidney disease 5 (3.2) 2 (3) 3 (3) 0.89
Chronic liver disease 17 (10.9) 7 (10) 10 (11) 0.88
Values are n (%) unless otherwise indicated.
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eases  [16] . Considerable efforts have been made to stan-
dardize nutritional treatment on an inpatient and outpa-
tient basis. National and international consensus com-
mittees developed and published guidelines focusing 
each on distinct medical conditions and different indica-
tions  [10, 11, 17–26] . Both societies, ASPEN and ESPEN, 
have published consensus guidelines on screening and 
nutritional therapy in patients undergoing HSCT  [10, 
11] . In brief, these guidelines recommend screening for 
malnutrition and early nutritional interventions if pa-
tients are unable to maintain an adequate nutritional in-
take (energy and proteins) on their own. It is recom-
mended that enteral nutrition should be the first choice 
feeding route in all patients with inadequate oral food 
intake and a functioning gastrointestinal tract  [2, 3] ; sup-
plemental parenteral nutrition is recommended in pa-
tients with inadequate food and enteral intake, for ex-
ample, patients with severe mucositis (grade >3), ileus, 
or intractable vomiting  [2, 3] . Still, there is lack of inter-
ventional data demonstrating who among the patient 
population would benefit most from nutritional inter-
ventions as well as regarding the optimal time point to 
start nutritional therapy, optimal route and optimal 
products are to be used  [13, 27] . Particularly, the AML 
patient population has not been studied in great detail. 
In this study, our analysis focused on nutritional status 
in AML patients before start of therapy and during HSCT 
and may help to close this gap.
 Our data are in line with previous studies looking at 
associations of nutritional parameters and outcomes in 
patients with haematological malignancies. One recent 
retrospective study from Japan including 145 adult pa-
tients who received allogeneic HSCT from 2000 to 2009 
reported a step-wise increase in the cumulative incidenc-
es of 2-year non-relapse mortality from 3.8% in the nor-
mal group up to 27.3% in the severe malnutrition group 
defined based on the post-HSCT weight loss of >10% 
 [28] . The same researchers also found that underweight 
patients before HSCT was a risk factor for mortality with 
a roughly 10% increase in risk  [29] . Our data validate 
these findings focusing on a specific patient group, that 
is, patients with AML and also reporting a variety of dif-
ferent outcomes including mortality, infectious compli-
cations and GvHD among others.
 In exploratory analyses, we did also investigate asso-
ciations of nutritional treatment as well glutamine use 
with outcomes. Importantly, because deterioration of nu-
tritional status is a strong risk predictor for adverse out-
come and patients receiving nutrition support in routine 
medical care in our analysis are per se at higher complica-
tion risk, we adjusted our analysis for important prognos-
tic indicators including the EBMT risk score, cytogenetics 
and comorbidities, as well as body weight before and dur-
ing HSCT. In the adjusted analysis, we did not find that 
nutritional therapy would reduce the risks associated 
with inadequate nutritional status but that in fact out-
comes were worse, and additional glutamine treatment 
did not show any effects on outcomes. Because of the ob-
servational design and residual confounding, the inter-
pretation of these results is challenging, maybe even mis-
leading and, thus, must be considered hypothesis-gener-
ating only. Nevertheless, this calls for larger randomised 
trials to investigate the effects of nutritional interventions 
in this high-risk patient population to establish causal ef-
fects.
 This report has limitations. First, this was a retrospec-
tive analysis of a prospective monocenter cohort study. 
Follow-up was based on clinical visits during routine 
medical care and variable in patients. Second, we focus 
on weight and weight loss only but did not investigate 
other nutritional parameters including body impedance 
analysis among others, which may help to better assess 
detailed body composition [30]. Third, for our explor-
atory analysis regarding parenteral nutrition and use of 
glutamine, patients were not randomised and despite ad-
justment for important prognostic indicators residual 
confounding is likely. Therefore, this analysis shows as-
sociations but does not suggest causality. Prospective in-
terventional trials are needed to better understand the 
impact of nutritional interventions in this vulnerable pa-
tient population.
 In conclusion, in patients with AML, low initial BMI 
and more pronounced weight loss during HSCT are 
strong prognostic indicators associated with lower sur-
vival and worse disease outcomes. Intervention research 
is needed to investigate whether adequate nutritional 
therapy can reverse these associations.
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 Appendix 
 Appendix 1. Association of parenteral nutrition and outcomes
Outcomes No parenteral 
nutrition
Parenteral 
nutrition
p value Use of parenteral nutrition,
multivariable OR/HR (95% CI)*
Therapy outcomes, n 66 90
Engraftment 62 (94) 90 (100) 0.018 HR 1.35 (0.95–1.93), p = 0.096
Mortality during index hospital stay 1 (2) 13 (14) 0.005 HR 9.48 (1.14–79.04), p = 0.038
Mortality within 100 days 5 (8) 20 (22) 0.014 HR 3.06 (1.07–8.77), p = 0.038
Overall mortality 36 (55) 53 (59) 0.59 HR 1.39 (0.88–2.22), p = 0.162
Recurrence of disease 31 (47) 37 (41) 0.47 HR 1.14 (0.68–1.93), p = 0.618
Complications associated with initial therapy
Development of fever 43 (65) 81 (90) <0.001 HR 1.91 (1.27–2.87), p = 0.002
Cumulative number of fever-days, mean (SD) 2.2 (2.9) 7.1 (6.3) <0.001 Difference 4.83 (3.06–6.61), p < 0.001
Number of recurrent fever episodes, mean (SD) 1.2 (1.3) 3.1 (2.3) <0.001 Difference 1.83 (1.16–2.49), p < 0.001
Mucositis 34 (52) 88 (98) <0.001 HR 5.64 (3.55–8.95), p = 0.000
Bacterial infection 48 (73) 73 (81) 0.21 OR 1.67 (0.71–3.92), p = 0.236
Blood stream infection 18 (27) 34 (38) 0.17 OR 1.66 (0.76–3.65), p = 0.207
Catheter-related infection 13 (20) 23 (26) 0.39 OR 1.46 (0.61–3.51), p = 0.393
Clostridium difficile infection 4 (6) 14 (16) 0.067 OR 4.06 (1.11–14.86), p = 0.035
Fungal infection 13 (20) 35 (39) 0.010 OR 2.95 (1.26–6.88), p = 0.012
Hospital-outcomes
Length of stay (index hospitalisation), mean (SD) 32.9 (9.4) 48.4 (24.8) <0.001 HR 14.10 (7.67–20.53), p < 0.001
Longterm complications
Intestinal GvHD 12 (18) 39 (43) <0.001 HR 2.38 (1.19–4.74), p = 0.014
GvHD of the skin 28 (42) 63 (70) <0.001 HR 1.99 (1.21–3.25), p = 0.006
Secondary cancer 4 (8) 6 (11) 0.55 OR 1.49 (0.25–8.70), p = 0.658
Infections during the first year 35 (56) 30 (38) 0.031 OR 0.47 (0.23–1.00), p = 0.049
Infections during the second year 24 (56) 14 (31) 0.019 OR 0.35 (0.13–0.94), p = 0.037
 * Multivariate model adjusted for for EBMT score, genetic information from the underlying disease, age, gender, comorbidities 
(coronary heart disease, valvular heart disease, congestive heart disease, diabetes, COPD, chronic kidney disease, chronic liver disease), 
initial BMI and weight loss.
Values are n (%) unless otherwise indicated. Bold refers to p values <0.1.
 Appendix 2. Association of glutamine use and outcomes in patients with parenteral nutrition
Outcomes No glutamine Glutamine p value Use of glutamin, 
multivariable OR/HR (95% CI)*
Therapy outcomes, n 36 54
Engraftment 36 (100) 54 (100) HR 0.52 (0.31 to 0.85), p = 0.009
Mortality during index hospital stay 5 (14) 8 (15) 0.90 HR 0.81 (0.21 to 3.12), p = 0.754
Mortality within 100 days 9 (25) 11 (20) 0.60 HR 0.53 (0.19 to 1.49), p = 0.230
Overall mortality 22 (61) 31 (57) 0.73 HR 0.88 (0.47 to 1.62), p = 0.678
Recurrence of disease 14 (39) 23 (43) 0.73 HR 0.75 (0.35 to 1.59), p = 0.449
Complications associated with initial therapy
Development of fever 34 (94) 47 (87) 0.25 HR 0.85 (0.52 to 1.39), p = 0.517
Cumulative number of fever-days, mean (SD) 7.0 (6.3) 7.1 (6.3) 0.96 Difference –0.28 (–3.26 to 2.69), p = 0.850
Number of recurrent fever episodes, mean (SD) 3.0 (2.0) 3.1 (2.5) 0.73 Difference –0.09 (–1.18 to 1.01), p = 0.877
Mucositis 36 (100) 52 (96) 0.24 HR 0.47 (0.28 to 0.78), p = 0.004
Bacterial infection 28 (78) 45 (83) 0.51 OR 1.81 (0.53 to 6.16), p = 0.345
Blood stream infection 12 (33) 22 (41) 0.48 OR 1.74 (0.63 to 4.82), p = 0.283
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Outcomes No glutamine Glutamine p value Use of glutamin, 
multivariable OR/HR (95% CI)*
Catheter-related infection 9 (25) 14 (26) 0.92 OR 1.15 (0.37 to 3.59), p = 0.806
Clostridium difficile infection 2 (6) 12 (22) 0.033 OR 4.15 (0.70 to 24.67), p = 0.118
Fungal infection 14 (39) 21 (39) 1.00 OR 0.92 (0.32 to 2.66), p = 0.881
Hospital-outcomes
Length of stay (index hospitalisation), mean (SD) 50.3 (26.4) 47.1 (23.8) 0.55 HR –3.86 (–14.35 to 6.64), p = 0.466
Longterm complications
Intestinal GvHD 13 (36) 26 (48) 0.26 HR 1.21 (0.56 to 2.64), p = 0.628
GvHD of the skin 27 (75) 36 (67) 0.40 HR 0.56 (0.31 to 0.99), p = 0.047
Secondary cancers 2 (11) 4 (12) 0.89 OR 2.23 (0.23 to 21.40), p = 0.486
Infections during the first year 4 (12) 26 (55) <0.001 OR 14.13 (3.02 to 66.06), p = 0.001
Infections during the second year 3 (17) 11 (41) 0.087 OR 7.37 (0.78 to 70.08), p = 0.082
 * Multivariate model adjusted for EBMT score, genetic information from the underlying disease, age, gender, comorbidities (coro-
nary heart disease, valvular heart disease, congestive heart disease, diabetes, COPD, chronic kidney disease, chronic liver disease), initial 
BMI and weight loss.
Values are n (%) unless otherwise indicated. Bold refers to p values <0.1.
 Appendix 2. (continued)
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